Abstract
Oncogenic driver mutations in several tumor types promote constitutive PD-L1 expression, a crucial ligand in PD-1-mediated tumor immune escape. Our studies in melanoma suggest a different mechanism–one of “adaptive immune resistance” in which PD-L1 expression is primarily driven by cytokine induction and is independent of BRAF mutational status.
Original language | English (US) |
---|---|
Journal | OncoImmunology |
Volume | 4 |
Issue number | 10 |
DOIs | |
State | Published - Oct 3 2015 |
Keywords
- BRAF
- PD-L1
- TIL
- adaptive immune resistance
- melanoma
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Oncology